查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608033

Hürthle 細胞癌症治療市場：按治療方法、最終用戶分類 - 全球預測 2025-2030 年

Hurthle Cell Carcinoma Treatment Market by Treatment (General Surgery, Radioactive Iodine, Robotic Surgery), End User (Ambulatory Surgical Center, Clinic, Hospital) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Hürthle細胞癌症治療市場2023年估值為64.4億美元，預計2024年將達到68.2億美元，複合年成長率為6.41%，到2030年將達到99.6億美元。

許特勒細胞癌 (HCC) 是一種罕見的甲狀腺癌，約佔分化型甲狀腺癌的 3% 至 5%。 HCC 研究和治療的範圍包括了解其生物學行為、診斷和有效的治療方法。對創新治療方法的需求至關重要，因為 HCC 往往對傳統治療方法有抵抗力，並且可能表現出攻擊行為。標靶治療、放射性碘治療、手術和新型藥物的應用對於控制這種疾病至關重要。最終用途範圍主要包括醫院、癌症治療中心和專門從事腫瘤學的研究機構。

主要市場統計
基準年[2023] 64.4億美元
預測年份 [2024] 68.2億美元
預測年份 [2030] 99.6億美元
複合年成長率（%） 6.41%

對肝細胞癌治療市場的洞察揭示了幾個關鍵的成長要素。甲狀腺疾病盛行率的上升、分子診斷的進步以及健康意識的提高對市場的擴張做出了重大貢獻。免疫療法和標靶藥物傳遞的最新發展顯示出進一步成長的潛力。診斷影像技術的進步也增強了早期檢測並促進及時介入。為了利用這些機會，相關人員應該投資個人化醫療研發，並與生技公司合作開發創新治療方法。然而，市場面臨治療成本上升、專用藥物供應有限以及對該疾病缺乏認知等挑戰，這些都阻礙了市場的成長。

創新和研究應著重於精準醫學的生物標記發現，從而提供量身定做的治療方案並改善患者的治療結果。包括新免疫療法在內的聯合治療的開發可能是提高 HCC 療效的有效方法。該市場競爭激烈但尚未開發，未滿足的臨床需求為進入市場提供了基礎。公司可以透過進行全面的臨床試驗來檢驗新治療方法，同時與醫療保健提供者密切合作以提高認知度和可及性，從而獲得競爭優勢。透過解決這些方面，公司可以在 Hürthle 細胞癌症治療市場中建立更好的地位。

市場動態：針對快速發展的 Hürthle 細胞癌症治療市場揭示的關鍵市場見解

Hürthle 細胞癌症治療市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助組織做出明智的投資決策、改善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 甲狀腺相關疾病增加
    • 提高有關治療需求的醫療保健意識
    • 政府舉措增多
  • 市場限制因素
    • 缺乏治療肝細胞癌的專家
  • 市場機會
    • 肝癌治療技術開發
    • 活性化肝細胞癌治療的研發
  • 市場挑戰
    • 化療的副作用和患者缺乏意識

波特五力：駕馭 Hürthle 細胞癌症治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 Hürthle 細胞癌症治療市場的外部影響

外部宏觀環境因素在塑造 Hürthle 細胞癌症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解 Hürthle 細胞癌症治療市場的競爭狀況

對 Hürthle 細胞癌症治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 Hürthle 細胞癌治療市場供應商的績效評估

FPNV 定位矩陣是評估 Hürthle 細胞癌症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃 Hürthle 細胞癌症治療市場的成功之路

對 Hürthle 細胞癌症治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 甲狀腺相關疾病增加
      • 提高有關治療需求的醫療保健意識
      • 政府加大力度
    • 抑制因素
      • 缺乏 HCC 治療的熟練專業人員
    • 機會
      • 肝癌治療技術進展
      • 擴大 HCC 治療的研發活動
    • 任務
      • 化療的副作用和患者缺乏意識
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 Hürthle 細胞癌治療市場（依治療）

  • 一般外科
  • 放射性碘
  • 機器人手術
  • 甲狀腺全切除手術

第7章 Hürthle 細胞癌症治療市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 醫院

第8章北美和南美Hürthle細胞癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區Hürthle細胞癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的Hürthle細胞癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Eurofins Scientific SE
  • Illumina Inc.
  • Merck KGaA
  • Novartis AG
  • PerkinElmer, Inc.
  • Pfizer, Inc.
  • Provell Pharmaceuticals, LLC
  • Qiagen NV
  • Sanofi SA
  • Sorrento Therapeutics, Inc.
  • Teikoku Seiyaku Co. Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0355054AC4AC

The Hurthle Cell Carcinoma Treatment Market was valued at USD 6.44 billion in 2023, expected to reach USD 6.82 billion in 2024, and is projected to grow at a CAGR of 6.41%, to USD 9.96 billion by 2030.

Hurthle Cell Carcinoma (HCC) is a rare form of thyroid cancer that accounts for approximately 3-5% of differentiated thyroid cancers. The scope of research and treatment for HCC involves understanding its biological behavior, diagnosis, and effective therapeutic approaches. The necessity for innovative treatment options is critical due to HCC's tendency to resist traditional therapies and its potential for aggressive behavior. The application of targeted therapies, radioactive iodine treatment, surgery, and novel drugs are pivotal in managing the disease. The end-use scope primarily involves hospitals, cancer treatment centers, and research institutions dedicated to oncology.

KEY MARKET STATISTICS
Base Year [2023] USD 6.44 billion
Estimated Year [2024] USD 6.82 billion
Forecast Year [2030] USD 9.96 billion
CAGR (%) 6.41%

Insights into the HCC treatment market reveal several key growth factors. Rising prevalence of thyroid disorders, advancements in molecular diagnostics, and increased health awareness contribute significantly to market expansion. Recent developments in immunotherapy and targeted drug delivery present potential opportunities for further growth. Technological advancements in diagnostic imaging also enhance early detection, thereby facilitating timely intervention. To capitalize on these opportunities, stakeholders should invest in R&D for personalized medicine and partner with biotech firms to develop innovative therapies. However, the market faces challenges such as high treatment costs, limited availability of specialized drugs, and a lack of awareness about the disease, which can hinder growth.

Innovation and research should focus on biomarker discovery for precision medicine, which could lead to tailored treatment options and improved patient outcomes. The development of combination therapies that include emerging immunotherapy options might offer a viable approach to improve efficacy against HCC. The nature of the market is competitive yet underdeveloped, driven by unmet clinical needs, which presents a fertile ground for market entry. Companies can gain a competitive edge by pursuing comprehensive clinical trials to validate new treatments while working closely with healthcare providers to enhance awareness and accessibility. By addressing these aspects, firms can better position themselves in the market for Hurthle Cell Carcinoma treatments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hurthle Cell Carcinoma Treatment Market

The Hurthle Cell Carcinoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing thyroid related diseases
    • Rising healthcare awareness about necessity of treatment
    • Increase in government initiatives
  • Market Restraints
    • Dearth of skilled professionals for the treatment of HCC
  • Market Opportunities
    • Technological developments in HCC treatment
    • Growing research and development activities of HCC treatment
  • Market Challenges
    • Adverse effects of the chemotherapy and lack of patient awareness

Porter's Five Forces: A Strategic Tool for Navigating the Hurthle Cell Carcinoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hurthle Cell Carcinoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hurthle Cell Carcinoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hurthle Cell Carcinoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hurthle Cell Carcinoma Treatment Market

A detailed market share analysis in the Hurthle Cell Carcinoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hurthle Cell Carcinoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hurthle Cell Carcinoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hurthle Cell Carcinoma Treatment Market

A strategic analysis of the Hurthle Cell Carcinoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hurthle Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Eurofins Scientific SE, Illumina Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer, Inc., Provell Pharmaceuticals, LLC, Qiagen N.V., Sanofi S.A., Sorrento Therapeutics, Inc., Teikoku Seiyaku Co. Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Hurthle Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across General Surgery, Radioactive Iodine, Robotic Surgery, and Total Thyroidectomy.
  • Based on End User, market is studied across Ambulatory Surgical Center, Clinic, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing thyroid related diseases
      • 5.1.1.2. Rising healthcare awareness about necessity of treatment
      • 5.1.1.3. Increase in government initiatives
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of skilled professionals for the treatment of HCC
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological developments in HCC treatment
      • 5.1.3.2. Growing research and development activities of HCC treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects of the chemotherapy and lack of patient awareness
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hurthle Cell Carcinoma Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. General Surgery
  • 6.3. Radioactive Iodine
  • 6.4. Robotic Surgery
  • 6.5. Total Thyroidectomy

7. Hurthle Cell Carcinoma Treatment Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Center
  • 7.3. Clinic
  • 7.4. Hospital

8. Americas Hurthle Cell Carcinoma Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Hurthle Cell Carcinoma Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Hurthle Cell Carcinoma Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agilent Technologies, Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Eli Lilly and Company
  • 6. Eurofins Scientific SE
  • 7. Illumina Inc.
  • 8. Merck KGaA
  • 9. Novartis AG
  • 10. PerkinElmer, Inc.
  • 11. Pfizer, Inc.
  • 12. Provell Pharmaceuticals, LLC
  • 13. Qiagen N.V.
  • 14. Sanofi S.A.
  • 15. Sorrento Therapeutics, Inc.
  • 16. Teikoku Seiyaku Co. Ltd.
  • 17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HURTHLE CELL CARCINOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TOTAL THYROIDECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023